Catalyst OrthoScience Inc.
Pioneers in Total Shoulder Arthroplasty

The growing prevalence of shoulder trauma and arthritis has led to a surge in demand for shoulder surgery. Among the effective treatments available, total shoulder arthroplasty (TSA) stands out as a viable option and is one of the fastest-growing markets in orthopedics. At the forefront of innovation in this segment is the pioneering medical device company, Catalyst OrthoScience. Its remarkable creation, the CSR Total Shoulder System, a stemless anatomic TSA implant, has garnered significant attention. This proprietary technology not only expedites recovery and restores mobility but also possesses a minimally invasive nature.

“At Catalyst OrthoScience, we specialize in shoulder arthroplasty, and our flagship product proudly distinguishes itself as the market’s sole offering with an anatomically designed stemless ellipsoid humeral head,” says Carl O’Connell, CEO and President of Catalyst OrthoScience.

What sets the CSR Total Shoulder System apart is its ingenuity in design, which mirrors the natural ellipsoid shape of the humeral head. The seamless monoblock structure and hassle-free press-fit design, along with the highly-patented precise surgical technique and instrumentation allow for a more accurate reconstruction of the natural center of rotation of the joint, and the versatility of the system allows it to address a broad range of surgical indications. Moreover, this system achieves significant preservation of the densest bone within the humeral head and allows for minimally invasive soft tissue approaches, a feat not achievable with traditional TSA device designs on the market today.

In addition to the CSR Total Shoulder System, Catalyst OrthoScience has introduced the R1 Reverse Shoulder System, a groundbreaking modern reverse shoulder implant.

Combining advanced surgical technology with a patientcentric approach, this system promotes precise implantation tailored to individual anatomies with minimal instrumentation and inventory. The streamlined preparation is one of the fastest on the market which can allow for reduced operating time, minimized anesthetic exposure, and greater bone preservation. The R1 Reverse Shoulder System was launched in 2022 and has already seen the successful treatment of over one-thousand patients at the time of this publication.

Expanding its array of commercially launched products, Catalyst OrthoScience presents the Archer 3D Targeting Software, currently in limited user release. This preoperative shoulder-planning software encompasses anatomic and reverse planning features, empowering surgeons to analyze each patient’s unique pathology meticulously and paving the way for exceptional personalized surgical plans.

While the CSR Total Shoulder System and the R1 Reverse Shoulder System meet the demand for modern TSA devices, Catalyst OrthoScience also strives to connect patients with surgeons in their vicinity via nationwide surgeon and patient education programs. Between a continually expanding portfolio, supporting local labs, attending national conferences, and hosting multiple National Symposium courses focused on addressing the latest clinical research and surgical techniques, Catalyst aims to bring more surgeons into the fold and build its market share. With over 300 centers in the United States utilizing their stemless TSA and reverse TSA implants, Catalyst OrthoScience is well on its way to an established presence in the market. These implants offer surgeons enhanced capabilities and contribute to superior outcomes compared to existing product lines on the market, and combined with the aforementioned educational efforts have resulted in record double-digit percentage revenue growth for the sales organization over the past few years. Although shoulder orthopedics is relatively young, the total shoulder arthroplasty market is predicted to continue to grow at over 8 percent and eclipse nearly USD 3 billion in revenue by 2030.

At Catalyst OrthoScience, we specialize in shoulder arthroplasty, and our flagship product proudly distinguishes itself as the market’s sole offering with an anatomically designed stemless ellipsoid humeral head

The company’s product portfolio has recently expanded with the FDA’s approval of its Stemmed CSR TSA system with ellipsoid heads, the first in the world with these traits. This expansion enhances the options available to surgeons, granting them greater flexibility within the operating room.

Catalyst takes pride in its capacity to conduct research, develop, and launch new products in under a year, which is possible due to its smaller size, dedicated engineering and marketing teams, and connection to a dedicated panel of key surgeon opinion leaders. Comparatively, the larger organizations in the shoulder arthroplasty world often take two to four years to develop and launch new products, which make it difficult to respond to the rapidly advancing clinical trends in the market. Catalyst OrthoScience remains resolute in its dedication to innovation and diversification, poised to shape the future of orthopedics and revolutionize the industry.